Andere talen Nabriva Therapeutics plc

Aandelen

NBRVF

IE000OZRGNV6

Vertraagde tijd OTC Markets Andere beurzen 15:31:27 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0001 ^USD	0,00%		0,00%	0,00%

2023	Nabriva Therapeutics plc rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2023	CI
2023	Sumitomo Pharma Co. (TSE:4506) verwierf Activa en rechten gerelateerd lefamulin in China, Hong Kong, Macau en Taiwan van Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH en Nabriva Therapeutics Ireland Dac voor $15 miljoen.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	19-10-23
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	31-07-23
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	31-07-23
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	24-07-23
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	10-07-23
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	07-07-23
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	07-07-23
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	22-05-23
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	17-04-23
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	17-04-23
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	17-04-23
Merck : fin de l'accord de distribution avec Nabriva	06-02-23
Nabriva Therapeutics : Material Agreement - Form 8-K	06-02-23
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	06-02-23
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	20-01-23
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	20-01-23
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	09-01-23
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	09-01-23
Nabriva Therapeutics Provides Corporate Update	09-01-23
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	06-01-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nabriva Therapeutics plc

Aandelen

NBRVF

IE000OZRGNV6

Andere talen

Filters